The Use of DPP-4 Inhibitors in Short Bowel Syndrome
- Conditions
- Short Bowel Syndrome
- Interventions
- Drug: Dipeptidyl peptidase-4 inhibitor
- Registration Number
- NCT02653131
- Lead Sponsor
- Stanley Dudrick's Memorial Hospital
- Brief Summary
The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
- Detailed Description
The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 8
- patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months
- stable metabolic status
- benign disease
- HPN < 12 months
- metabolically unstable
- cancer as the reason for intestinal failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description DPP-4 Dipeptidyl peptidase-4 inhibitor The administration of the DPP-4 inhibitor in the form of a pill once per day
- Primary Outcome Measures
Name Time Method Improvement of intestinal absorption 12 months the use of DPP-4 inhibitor results in the better intestinal absorption
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Stanley Dudrick's Memorial Hospital
🇵🇱Skawina, Poland